NanoSyrinx
NanoSyrinx is a synthetic biology company developing a next-generation platform technology for targeted intracellular delivery of biological molecules. The company engineers bacterial nanomachines called Nanosyringes, inspired by one of Nature's own elegant solutions, to enable targeted intracellular delivery of protein therapeutics such as antibodies and peptides. This addresses the critical challenge that over 80%…
Funding snapshot
About
NanoSyrinx is a synthetic biology company developing a next-generation platform technology for targeted intracellular delivery of biological molecules. The company engineers bacterial nanomachines called Nanosyringes, inspired by one of Nature's own elegant solutions, to enable targeted intracellular delivery of protein therapeutics such as antibodies and peptides. This addresses the critical challenge that over 80% of intracellular targets remain undruggable due to poor bioavailability. Building on over a decade of fundamental research, NanoSyrinx's platform aims to unlock the interior of the cell and the myriad therapeutic opportunities within. The company has been featured in Nature Biopharma Dealmakers and has attracted experienced biotherapeutics leadership including a CEO with 25+ years of experience who has secured over $500 million in funding. Founded in 2018 and headquartered in Coventry, United Kingdom, NanoSyrinx has raised $21.6M in Series A funding from investors including M Ventures, Octopus Ventures, IQ Capital, BGF, Lilly, and UK Innovation Science & Seed Fund.
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drugs,
Drug Delivery > Nanoparticle Based
Team background
College Wise > University of Cambridge, University of Warwick
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.